Improving systemic therapies for metastatic disease have led to an increasing incidence of brain metastasis for patients with solid malignancies. Patients diagnosed with brain metastasis, meanwhile, are benefiting from a rapidly proliferating body of CNS-directed research that, appropriately applied, can lead to improved survival and quality of life. In selected cases of brain metastasis, radiosurgery and hypofractionated stereotactic radiotherapy (SRT) may be used either in lieu of, or in combination with invasive neurosurgery. The appropriate selection of therapy, and in the case of combined therapy, the sequencing - neoadjuvant versus adjuvant radiosurgery - should be predicated upon the risk/benefit ratio of each to the individual. This requires familiarity with novel contemporary observations culled from a large body of recent literature. This session is designed to familiarize the audience with the key considerations necessary to individualize decision-making and to equip them with the necessary skills for competent treatment of patients eligible for neurosurgery and/or radiosurgery for brain metastasis. A case-based approach will be used to contextualize novel concepts and facilitate learning.